Glaxo Loses Bid to Toss Vectura Verdict Over Lung Inhalers

A U.S. appeals court let stand a $89.7 million jury verdict that GlaxoSmithKline infringed a Vectura patent for particles used in inhalers.

• Jury had found that Glaxo’s Breo, Anoro and Incruse, which Glaxo began selling in 2013 as part of its Ellipta suite of treatments, have technology owned by Vectura that helps disperse the medicine deep inside the lungs
• Glaxo had argued that the jury got it wrong when it found infringement, and sought a new trial on damages for what it claimed were “flaws in the calculation of the royalty proposed by Vectura’s damages expert”
• The damages were based ...